Clinical Trial: Levetiracetam in the Treatment of Neuroleptic-induced Tardive Dyskinesia
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: An 8-week Exploratory, Double-blind, Placebo Controlled, Randomized Trial: Evaluation of the Efficacy and Safety of Levetiracetam up to 3000 mg/Day (250-500 mg Oral Tablets in b.i.d. Administration) o
Brief Summary: An 8-week study to examine safety and efficacy of levetiracetam in patients with neuroleptic-induced tardive dyskinesia
Detailed Summary:
Sponsor: UCB Pharma
Current Primary Outcome: Reduction in neuroleptic-induced tardive dyskinesia over an 8 week treatment period
Original Primary Outcome: Same as current
Current Secondary Outcome:
- Neuroleptic-induced akathisia and other extrapyramidal symptoms ,
- Effect on the primary psychiatric disorder
- Safety
Original Secondary Outcome: Same as current
Information By: UCB Pharma
Dates:
Date Received: September 9, 2005
Date Started: May 2005
Date Completion:
Last Updated: December 5, 2013
Last Verified: September 2009